Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Chiron To Meet With U.K. Regulatory Authorities On Fluvirin Suspension

This article was originally published in The Pink Sheet Daily

Executive Summary

The company does not anticipate the three-month manufacturing suspension will be lifted following the Oct. 6 meeting. Chiron's projected 48 mil. doses of flu vaccine were expected to account for nearly 50% of the U.S. supply.

You may also be interested in...



Flu Vaccine Manufacturing With Canine Kidney Cells To Be Discussed By Committee In November

FDA's vaccines advisory committee will discuss Madin-Darby canine kidney cells for flu vaccine manufacturing Nov. 16. Solvay submitted a drug master file for a canine cell-based influenza vaccine in June.

Flu Vaccine Manufacturing With Canine Kidney Cells To Be Discussed By Committee In November

FDA's vaccines advisory committee will discuss Madin-Darby canine kidney cells for flu vaccine manufacturing Nov. 16. Solvay submitted a drug master file for a canine cell-based influenza vaccine in June.

Chiron Expects Full Fluvirin Vaccine Production In 2006-2007

Fluvirin flu vaccine production capacity for 2005-2006 will be lower than the previous estimate of 18 mil.-25 mil. doses due to a shortened production season, CEO Pien says.

Related Content

Topics

UsernamePublicRestriction

Register

PS061210

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel